Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
Alvares CL, Davies FE, Horton C, Patel G, Powles R, Sirohi B, Zuha R, Gatt A, Saso R, Treleaven JG, Dearden CE, Potter MN, Ethell ME, Morgan GJ. Alvares CL, et al. Among authors: potter mn. Br J Haematol. 2005 Jun;129(5):607-14. doi: 10.1111/j.1365-2141.2005.05514.x. Br J Haematol. 2005. PMID: 15916682 Free article.
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis.
Wu P, Davies FE, Horton C, Jenner MW, Krishnan B, Alvares CL, Saso R, McCormack R, Dines S, Treleaven JG, Potter MN, Ethell ME, Morgan GJ. Wu P, et al. Among authors: potter mn. Leuk Lymphoma. 2006 Nov;47(11):2335-8. doi: 10.1080/10428190600821955. Leuk Lymphoma. 2006. PMID: 17107906
Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis.
Anoop P, Shaw BE, Riley U, Ethell ME, Taj M, Lancaster DL, Atra A, Saso R, Littlewood S, Mohammed K, Davies F, Treleaven J, Morgan GJ, Potter MN. Anoop P, et al. Among authors: potter mn. Hematology. 2011 Jul;16(4):213-20. doi: 10.1179/102453311X13025568941763. Hematology. 2011. PMID: 21756537
Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.
Shaw BE, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL. Shaw BE, et al. Among authors: potter mn. Br J Haematol. 2011 Apr;153(2):244-52. doi: 10.1111/j.1365-2141.2011.08615.x. Epub 2011 Mar 8. Br J Haematol. 2011. PMID: 21382020 Free article. Clinical Trial.
Diagnosis and management of acute graft-versus-host disease.
Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, Hadzic N, Shaw BE, Potter MN; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Dignan FL, et al. Among authors: potter mn. Br J Haematol. 2012 Jul;158(1):30-45. doi: 10.1111/j.1365-2141.2012.09129.x. Epub 2012 Apr 26. Br J Haematol. 2012. PMID: 22533831 Free article.
170 results